Business Wire·Sep 14, 2026, 4:05 PM ET

Contineum Therapeutics Reports Phase 2 Results for JNJ-5120/PIPE-307 for the Treatment of Major Depressive Disorder

Contineum Therapeutics announced that its Phase 2 MOONLIGHT-1 trial failed to meet the primary efficacy endpoint for JNJ-5120/PIPE-307.
The primary endpoint assessed improvement from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score at Day 5 compared to placebo.
JNJ-5120/PIPE-307 was well-tolerated with no new safety signals observed during the study.
Johnson & Johnson is currently analyzing trial data including prespecified exploratory endpoints to determine next steps for the drug candidate.
The MOONLIGHT-1 study was a randomized, double-blind, multicenter, placebo-controlled, proof-of-concept trial evaluating JNJ-5120/PIPE-307 as monotherapy in adults with major depressive disorder.
PIPE-307 is being developed by Johnson & Johnson under a global license & development agreement with Contineum Therapeutics.
Contineum Therapeutics remains focused on its pipeline of small molecule therapies including PIPE-791 for idiopathic pulmonary fibrosis & chronic pain.
The release includes standard forward-looking statements warning of risks related to clinical trial outcomes, regulatory approval, & reliance on third-party partners.